Belinda R Lennox1, Emma C Palmer-Cooper2, Thomas Pollak3, Jane Hainsworth2, Jacqui Marks2, Leslie Jacobson4, Bethan Lang4, Hannah Fox5, Berne Ferry5, Linda Scoriels6, Hannah Crowley2, Peter B Jones7, Paul J Harrison2, Angela Vincent4. 1. Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK. Electronic address: belinda.lennox@psych.ox.ac.uk. 2. Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK. 3. Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. 4. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. 5. Department of Clinical Laboratory Immunology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. 6. Department of Psychiatry, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK; Institute of Psychiatry, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 7. Department of Psychiatry, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.
Abstract
BACKGROUND: Psychosis is a common presenting feature in antibody-mediated encephalitis, for which prompt recognition and treatment usually leads to remission. We aimed to investigate whether people with circumscribed schizophrenia-like illnesses have such antibodies-especially antibodies against the N-methyl-D-aspartate receptor (NMDAR)-more commonly than do healthy controls. METHODS: We recruited patients aged 14-35 years presenting to any of 35 mental health services sites across England with first-episode psychosis, less than 6 weeks of treatment with antipsychotic medication, and a score of 4 or more on at least one selected Positive and Negative Syndrome Scale (PANSS) item. Patients and controls provided venous blood samples. We completed standardised symptom rating scales (PANSS, ACE-III, GAF) at baseline, and tested serum samples for antibodies against NMDAR, LGI1, CASPR2, the GABAA receptor, and the AMPA receptor using live cell-based assays. Treating clinicians assessed outcomes of ICD diagnosis and functioning (GAF) at 6 months. We included healthy controls from the general population, recruited as part of another study in Cambridge, UK. FINDINGS: Between Feb 1, 2013, and Aug 31, 2014, we enrolled 228 patients with first-episode psychosis and 105 healthy controls. 20 (9%) of 228 patients had serum antibodies against one or more of the neuronal cell surface antibodies compared with four (4%) of 105 controls (unadjusted odds ratio 2·4, 95% CI 0·8-7·3). These associations remained non-significant when adjusted for current cigarette smoking, alcohol consumption, and illicit drug use. Seven (3%) patients had NMDAR antibodies compared with no controls (p=0·0204). The other antibodies did not differ between groups. Antibody-positive patients had lower PANSS positive, PANSS total, and catatonia scores than did antibody-negative patients. Patients had comparable scores on other PANSS items, ACE-III, and GAF at baseline, with no difference in outcomes at 6 months. INTERPRETATION: Some patients with first-episode psychosis had antibodies against NMDAR that might be relevant to their illness, but did not differ from patients without NMDAR antibodies in clinical characteristics. Our study suggests that the only way to detect patients with these potentially pathogenic antibodies is to screen all patients with first-episode psychosis at first presentation. FUNDING: Medical Research Council.
BACKGROUND:Psychosis is a common presenting feature in antibody-mediated encephalitis, for which prompt recognition and treatment usually leads to remission. We aimed to investigate whether people with circumscribed schizophrenia-like illnesses have such antibodies-especially antibodies against the N-methyl-D-aspartate receptor (NMDAR)-more commonly than do healthy controls. METHODS: We recruited patients aged 14-35 years presenting to any of 35 mental health services sites across England with first-episode psychosis, less than 6 weeks of treatment with antipsychotic medication, and a score of 4 or more on at least one selected Positive and Negative Syndrome Scale (PANSS) item. Patients and controls provided venous blood samples. We completed standardised symptom rating scales (PANSS, ACE-III, GAF) at baseline, and tested serum samples for antibodies against NMDAR, LGI1, CASPR2, the GABAA receptor, and the AMPA receptor using live cell-based assays. Treating clinicians assessed outcomes of ICD diagnosis and functioning (GAF) at 6 months. We included healthy controls from the general population, recruited as part of another study in Cambridge, UK. FINDINGS: Between Feb 1, 2013, and Aug 31, 2014, we enrolled 228 patients with first-episode psychosis and 105 healthy controls. 20 (9%) of 228 patients had serum antibodies against one or more of the neuronal cell surface antibodies compared with four (4%) of 105 controls (unadjusted odds ratio 2·4, 95% CI 0·8-7·3). These associations remained non-significant when adjusted for current cigarette smoking, alcohol consumption, and illicit drug use. Seven (3%) patients had NMDAR antibodies compared with no controls (p=0·0204). The other antibodies did not differ between groups. Antibody-positive patients had lower PANSS positive, PANSS total, and catatonia scores than did antibody-negative patients. Patients had comparable scores on other PANSS items, ACE-III, and GAF at baseline, with no difference in outcomes at 6 months. INTERPRETATION: Some patients with first-episode psychosis had antibodies against NMDAR that might be relevant to their illness, but did not differ from patients without NMDAR antibodies in clinical characteristics. Our study suggests that the only way to detect patients with these potentially pathogenic antibodies is to screen all patients with first-episode psychosis at first presentation. FUNDING: Medical Research Council.
Authors: F Graus; A Boronat; X Xifró; M Boix; V Svigelj; A García; A Palomino; L Sabater; J Alberch; A Saiz Journal: Neurology Date: 2010-03-09 Impact factor: 9.910
Authors: Karina S MacDowell; Borja García-Bueno; José L M Madrigal; Mara Parellada; Celso Arango; Juan A Micó; Juan C Leza Journal: Int J Neuropsychopharmacol Date: 2011-12-16 Impact factor: 5.176
Authors: Sarosh R Irani; Katarzyna Bera; Patrick Waters; Luigi Zuliani; Susan Maxwell; Michael S Zandi; Manuel A Friese; Ian Galea; Dimitri M Kullmann; David Beeson; Bethan Lang; Christian G Bien; Angela Vincent Journal: Brain Date: 2010-06 Impact factor: 13.501
Authors: Esther Castillo-Gomez; Anne Kästner; Johann Steiner; Anja Schneider; Bilke Hettling; Giulia Poggi; Kristin Ostehr; Manfred Uhr; Abdul R Asif; Mike Matzke; Ulrike Schmidt; Viktoria Pfander; Christian Hammer; Thomas F Schulz; Lutz Binder; Winfried Stöcker; Frank Weber; Hannelore Ehrenreich Journal: Ann Neurol Date: 2015-12-02 Impact factor: 10.422
Authors: Michael S Zandi; Sarosh R Irani; Bethan Lang; Patrick Waters; Peter B Jones; Peter McKenna; Alasdair J Coles; Angela Vincent; Belinda R Lennox Journal: J Neurol Date: 2010-10-26 Impact factor: 4.849
Authors: Philippa Pettingill; Holger B Kramer; Jan Adriaan Coebergh; Rosie Pettingill; Susan Maxwell; Anjan Nibber; Andrea Malaspina; Anu Jacob; Sarosh R Irani; Camilla Buckley; David Beeson; Bethan Lang; Patrick Waters; Angela Vincent Journal: Neurology Date: 2015-01-30 Impact factor: 9.910
Authors: Sarosh R Irani; Charlotte J Stagg; Jonathan M Schott; Clive R Rosenthal; Susanne A Schneider; Philippa Pettingill; Rosemary Pettingill; Patrick Waters; Adam Thomas; Natalie L Voets; Manuel J Cardoso; David M Cash; Emily N Manning; Bethan Lang; Shelagh J M Smith; Angela Vincent; Michael R Johnson Journal: Brain Date: 2013-09-06 Impact factor: 13.501
Authors: Ludger Tebartz van Elst; Karl Bechter; Harald Prüss; Alkomiet Hasan; Jo Hann Steiner; Frank Leypoldt; Dominique Endres Journal: Nervenarzt Date: 2019-07 Impact factor: 1.214